Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aileron Therapeutics Inc (ALRN)

Aileron Therapeutics Inc (ALRN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Aileron Therapeutics Initiates Enrollment in Schedule Optimization Part of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent in Small Cell Lung Cancer (SCLC) Patients Being Treated with Topotecan

-- Novel approach leverages the ability of intracellular p53 protein to induce cell cycle arrest in healthy cells to prevent severe toxicities driven by chemotherapy's off-target effects --

ALRN : 0.8700 (-0.96%)
Aileron Therapeutics Announces Closing of Public Offering of Common Stock and Exercise of Option to Purchase Additional Shares

Aileron Therapeutics (NASDAQ: ALRN) announced today the closing of its underwritten public offering of its common stock, including the exercise by the underwriter of their option to purchase an additional...

ALRN : 0.8700 (-0.96%)
Aileron Therapeutics Announces Pricing of Public Offering of Common Stock

Aileron Therapeutics (NASDAQ: ALRN) announced today the pricing of an underwritten public offering of 9,090,910 shares of its common stock at a public offering price of $1.10 per share, for aggregate gross...

ALRN : 0.8700 (-0.96%)
Aileron Therapeutics Announces Proposed Public Offering of Common Stock

Aileron Therapeutics (NASDAQ: ALRN) announced today that it has commenced an underwritten public offering of shares of its common stock. Aileron also intends to grant the underwriter a 30-day option to...

ALRN : 0.8700 (-0.96%)
The Zacks Analyst Blog Highlights: Aileron Therapeutics, Energy Focus, MicroVision, Mersana Therapeutics and CymaBay Therapeutics

The Zacks Analyst Blog Highlights: Aileron Therapeutics, Energy Focus, MicroVision, Mersana Therapeutics and CymaBay Therapeutics

CBAY : 3.33 (+0.30%)
EFOI : 4.70 (-7.84%)
MVIS : 1.6700 (+7.05%)
ALRN : 0.8700 (-0.96%)
MRSN : 21.25 (+3.21%)
Thinking about buying stock in Ovid Therapeutics, Celsion Corp, Aileron Therapeutics, Cronos Group, or Bank of America?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OVID, CLSN, ALRN, CRON, and BAC.

ALRN : 0.8700 (-0.96%)
BAC : 24.14 (-0.21%)
CLSN : 1.2500 (-3.10%)
OVID : 7.39 (+5.57%)
5 Top Stocks Up 100%+ in May With More Room to Run

Reopening of the economy, vaccine hopes and stimulus measures helped Wall Street climb north in May and squash the old adage "sell in May and go away."

MRK : 78.25 (+1.16%)
MRNA : 75.04 (+4.54%)
NVAX : 109.97 (+5.42%)
CBAY : 3.33 (+0.30%)
EFOI : 4.70 (-7.84%)
MVIS : 1.6700 (+7.05%)
ALRN : 0.8700 (-0.96%)
MRSN : 21.25 (+3.21%)
Aileron Therapeutics Announces Positive Interim Results from Phase 1b/2 Clinical Trial of ALRN-6924 for the Prevention of Topotecan-induced Toxicities During Treatment for Small Cell Lung Cancer

- - -

ALRN : 0.8700 (-0.96%)
Thinking about buying stock in PhaseBio Pharmaceuticals, Aileron Therapeutics, JetBlue Airways, Aurora Cannabis, or Remark Holdings?

ALRN : 0.8700 (-0.96%)
ACB : 11.75 (-2.73%)
Aileron Therapeutics Announces Initiation of Expansion Cohort and First Patient Enrolled into Expansion Cohort of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent

Aileron Therapeutics (NASDAQ:ALRN) announced today the expansion of one of the dose levels in the dose optimization part of its Phase 1b/2 clinical trial evaluating ALRN-6924 as an agent to protect patients...

ALRN : 0.8700 (-0.96%)
Aileron Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

Enrollment completed in the dose optimization part of the ongoing Phase 1b/2 clinical trial of ALRN-6924 as a chemoprotection agent in cancer patients

ALRN : 0.8700 (-0.96%)
Aileron Therapeutics Announces Plans to Release Interim Results from its Phase 1b/2 Myelopreservation Study in Mid-2020

Presentation of interim results from the dose-optimization part of the Phase 1b myelopreservation study

ALRN : 0.8700 (-0.96%)
Aileron Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

Phase 1b/2 clinical trial of ALRN-6924 as a myelopreservation agent for the protection against chemotherapy-induced toxicity in small cell lung cancer started dosing patients September 2019; interim data...

ALRN : 0.8700 (-0.96%)
Aileron Therapeutics Announces the Promotion of Richard J. Wanstall to Chief Financial Officer and Treasurer

Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, announced today the promotion of Richard J. Wanstall to Chief Financial Officer and...

ALRN : 0.8700 (-0.96%)
Aileron Therapeutics Reports Third Quarter 2019 Results

Announced positive interim results from its ongoing Phase 2a clinical trial evaluating the combination of ALRN-6924 and Pfizer's IBRANCE(R) (palbociclib) for the treatment of patients with tumors harboring...

ALRN : 0.8700 (-0.96%)
Aileron Therapeutics to Report Third Quarter 2019 Financial Results on November 7th

Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, today announced that the Company will host a conference call and webcast at 8:30 a.m....

ALRN : 0.8700 (-0.96%)
Aileron Therapeutics Announces Positive Nonclinical Myelopreservation Results for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference

Nonclinical research results show that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells and enhanced the anti-cancer activity of chemotherapy

ALRN : 0.8700 (-0.96%)
Aileron to Present Nonclinical Myelopreservation Data for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference on October 29th

Nonclinical research showed that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells without inhibiting the anti-cancer activity of chemotherapy.

ALRN : 0.8700 (-0.96%)
Aileron Therapeutics Announces the Initiation of Patient Treatment in its First Clinical Ph1b/2 Trial of ALRN-6924 as a Myelopreservation Agent

Treatment uses a precision-medicine strategy to prevent the toxic side-effects of chemotherapy in patients with p53-mutated cancer, representing approximately 50% of all patients with cancer.

ALRN : 0.8700 (-0.96%)
Aileron Presents Positive Interim Phase 2a Data for ALRN-6924 in Combination with Pfizer's Palbociclib at the 2019 Congress of the European Society for Medical Oncology

Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer patients, announced the presentation of interim results from its ongoing...

ALRN : 0.8700 (-0.96%)

Van Meerten Stock Picks

Ebay - Pick of the Day
Today Ebay (EBAY) is a Volume Leader on Barchart: 100% technical buy signals Trend Spotter buy signal Above its 20, 50 and 100 Day moving averages 16 new highs and up 26.
EBAY +0.78
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar